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Abstract 26 
Wafers combining weight ratios of Polyox with carrageenan (75/25) or sodium alginate (50/50) 27 
containing streptomycin and diclofenac were prepared to improve chronic wound healing. Gels 28 
were freeze dried using a lyophilisation cycle incorporating an annealing step. Wafers were 29 
characterised for morphology, mechanical and in vitro functional (swelling, adhesion, drug 30 
release in the presence of simulated wound fluid) characteristics. Both blank and drug loaded 31 
wafers were soft, flexible, elegant in appearance and non-brittle in nature. Annealing helped to 32 
improve porous nature of wafers but was affected by addition of drugs. Mechanical 33 
characterisation demonstrated that the wafers were strong enough to withstand normal stresses 34 
but also flexible to prevent damage to newly formed skin tissue. Differences in swelling, 35 
adhesion and drug release characteristics could be attributed to differences in pore size and 36 
sodium sulphate formed due to salt forms of the two drugs. Blank wafers showed relatively 37 
higher swelling and adhesion than drug loaded wafers with the latter showing controlled release 38 
of streptomycin and diclofenac. The optimised dressing has the potential to reduce bacterial 39 
infection and can also help to reduce swelling and pain associated with injury due to the anti-40 
inflammatory action of diclofenac and help to achieve more rapid wound healing. 41 
 42 
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1 Introduction 76 
According to the Wound Healing Society (WHS), a wound is the consequence of 77 
disruption of normal anatomic structure and function. It usually describes the rupture or defect in 78 
skin or body tissue due to physical or thermal damage or a consequence of underlying 79 
physiological and medical conditions1. The wound healing process is a complex phenomenon 80 
and involves different phases such as haemostasis, inflammation, proliferation, remodelling and 81 
scar maturation which are discussed elsewhere1-3. Based on the nature of the repair process, 82 
wounds are classified as acute and chronic. Compared with acute wounds, chronic wounds 83 
represent a medical challenge due to various complicating factors including diabetes and 84 
malignancies, chronic systemic inflammation, persistent infection, destruction of neighbouring 85 
tissues, poor primary treatment and other patient related factors such as poor nutrition4.  86 
The management of chronic wounds places an enormous drain on healthcare resources; 87 
with some studies estimating the cost of wound care management to the UK National Health 88 
Service (NHS) to be about £1billion a year. In the UK, around 24,000 admissions a year involve 89 
patients with diabetic foot ulceration alone, thereby costing the NHS some £17million5. Winter’s 90 
theory of wound healing introduced a new approach for achieving rapid wound healing by 91 
maintaining a moist environment around the wound6. This principle of moist wound healing 92 
formed the basis of increased demand for developing a new range of modern wound dressings 93 
that can absorb excess of exudate and allow the maintenance of adequate moisture at wound 94 
surfaces. Further, different types of wounds (e.g. acute, chronic, exuding and dry wound) also 95 
affect the choice of dressing and in fact, no single dressing fulfils all the requirements (ideal 96 
characteristics) suitable for the management of all wounds1.  97 
Wound exudate from acute wounds contains many endogenous substances which 98 
typically reflect the overall wound healing process. These include epithelial and fibroblast cells 99 
which have been shown to increase the rate and quality of wound healing7. On the other hand, 100 
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most chronic wound exudates are associated with bacteria, dead white cells in combination with 101 
high levels of inflammatory mediators and protein-digesting enzymes which can be unfavourable 102 
for the wound healing process8. In modern wound care practice, iodine, silver and broad 103 
spectrum germicidal agents such as neomycin, bacitracin, polymyxin, STP, gentamycin and/or 104 
combinations are used to control and treat bacterial infection in chronic wounds. Local delivery 105 
of these antibiotics in the form of dressings is more convenient over their systemic counterparts 106 
since they deliver a higher concentration of medication directly to the desired area and are less 107 
frequently implicated in causing bacterial resistance9. 108 
Polysaccharides, being naturally occurring biomolecules, are an obvious choice for 109 
application as potential wound management aids10. It has been previously demonstrated that the 110 
use of synthetic and natural polymers helps to improve the properties which makes them suitable 111 
for application in the biomedical field11. Pawar and co-authors prepared films from blends of 112 
synthetic and natural polymers for potential improvement in chronic wound healing12. However, 113 
highly exuding chronic wounds such as diabetic foot and venous ulcers limit the application of 114 
film dressings due to the high amount of exudate produced. Film dressings being poor at 115 
absorbing large volumes of exudate, allow the fluid to collect beneath the dressing, causing 116 
maceration at the wound site and therefore require frequent dressing changes which adversely 117 
affects patient compliance.  118 
Lyophilised wafers are produced by freeze-drying polymer solutions and gels to yield 119 
solid porous structures that can easily be applied to exuding wound surfaces13. It is anticipated 120 
that a lyophilised polymer matrix would preserve the size, shape and form of contained 121 
compounds unlike a conventional gel suspension, where crystal ripening, agglomeration and 122 
polymorphic changes may occur14. Their physical architecture resembles those of foam dressings 123 
which are made of porous polyurethane. Drug stability is better in a lyophilised dosage form 124 
compared to a semi-solid hydrogel based formulation15. Lyophilized wafers provide a potential 125 
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means of delivering pharmacological agents to wound surfaces to aid healing16. They have the 126 
ability to incorporate soluble and insoluble antimicrobial compounds greater than their minimum 127 
bactericidal concentration for antibacterial activity against pathogenic bacteria17. Wafers have 128 
the capacity to absorb large amounts of exudate due to their porous nature whilst maintaining a 129 
moist environment without damaging newly formed tissue. Wafers also offer high drug loading 130 
capacity compared to solvent cast films18. 131 
This study involves preparation and functional characterisation of lyophilised wafers of 132 
Polyox (POL) in combination with carrageenan (CAR) or sodium alginate (SA) loaded with 133 
streptomycin (antibacterial) and diclofenac (anti-inflammatory) to target infection and the 134 
inflammatory phase of wound healing. The prepared wafers were characterised by scanning 135 
electron microscopy (SEM), X-ray diffraction (XRD), Fourier transform infrared spectroscopy 136 
(FTIR) and mechanical properties using texture analyser. The optimised wafers were further 137 
evaluated for functional bio-analytical properties such as swelling, adhesion and drug release 138 
properties.  139 
 140 
2  Experimental 141 
2.1 Materials 142 
 Polyethylene oxide (Polyox™ WSR 301 ≈4000 kDa) was obtained as a gift from 143 
Colorcon Ltd (Dartford, UK), κ-carrageenan (Gelcarin GP 812 NF) was obtained from IMCD 144 
Ltd (Sutton, UK), sodium hexane sulphonate, sodium phosphate tribasic, dodecahydrate (>98%), 145 
bovine serum albumin (BSA), diclofenac sodium (DLF) and streptomycin sulphate (STP) were 146 
all purchased from Sigma Aldrich, (Gillingham, UK). Sodium alginate (SA), acetonitrile (HPLC 147 
grade), glycerol (GLY), tris (hydroxy) aminomethane, calcium chloride dihydrate, ethanol 148 
(laboratory grade), orthophosphoric acid (analytical grade) were all purchased from Fisher 149 
Scientific (Leicestershire, UK).  150 
Page 6 of 45Journal of Pharmaceutical Sciences
7 
 
2.2  Preparation of POL-CAR and POL-SA gels 151 
Blank (BLK) polymeric gels (1% w/w) of polyox (POL) and carrageenan (CAR) and 152 
POL and sodium alginate (SA) were prepared according to previously reported methods12,19. In 153 
brief, blends of POL with CAR and POL with SA (weight ratio of 75/25 and 50/50) respectively 154 
yielding 1% w/w of total polymer weight, were prepared by stirring on a magnetic stirrer at 70°C 155 
to form a uniform gel. The drug loaded (DL) gels were prepared by the addition of an ethanolic 156 
solution of DLF to the polymeric gel (as described above) at 70°C to obtain a final DLF 157 
concentration of 10 and 25% w/w. respectively for POL-SA and POL-CAR gels. The gel was 158 
subsequently cooled to 40°C with constant stirring and an aqueous solution of STP was 159 
subsequently added to achieve a final STP concentration of 25 and 30% w/w respectively for 160 
POL-SA and POL-CAR gels. The amounts of the polymers and drugs used for the preparation of 161 
gels are summarised in Table 1.  162 
 163 
2.3 Freeze drying cycle development 164 
Prior to lyophilisation, preliminary DSC studies on the BLK (POL-CAR and POL-SA) 165 
gels were carried out. A differential scanning calorimeter DSC-1 (Mettler Toledo Ltd, Leicester, 166 
UK), calibrated with indium (at 10°C/min) was used to analyse the thermal events in the gels to 167 
determine a more suitable lyophilisation cycle. The blank (BLK) gels were cooled in 40 µl 168 
aluminium pans (ME-00026763, Metler Toledo) from 25 to -60°C at a rate of 10°C/min. They 169 
were then re-heated back to 25 °C at 20 °C/min and the cycle repeated three times. Based on 170 
thermal events observed during the heating cycles, an annealing temperature of -25°C was 171 
chosen. The samples were then cooled to -60°C, warmed to -25°C, held at that temperature for 172 
10 min, cooled back to -60°C and then warmed through to 25°C at 20°C/min. 173 
 174 
 175 
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2.4 Wafer preparation 176 
The freeze-dried wafers were prepared by freeze-drying (10 gm) of each homogeneous 177 
gel in 6 well moulds (diameter 35 mm) (Corning® CellBIND® Sigma Aldrich, Gillingham, UK) 178 
in a Virtis Advantage XL 70 freeze dryer (Biopharma Process Systems, Winchester, UK) using 179 
an automated novel lyophilisation cycle (Figure 1). This involved initially cooling and freezing 180 
including annealing step for samples from room temperature to -5°C and then -50°C over a 181 
period of 10 h (at 200 mTorr). An annealing step at -25°C for 2 h was applied and its effect on 182 
the drug loaded formulation investigated. The frozen samples were then heated in a series of 183 
thermal ramps to -25°C under vacuum (20-50 mTorr) over a 24 h period. Secondary drying of 184 
the wafers was carried out at 20°C (10 mTorr) for 7 h. The wafers were designated as ‘An’ 185 
(annealed) or ‘NAn’ (non-annealed). 186 
 187 
2.5 Scanning electron microscopy (SEM) 188 
 Surface morphology of the lyophilised wafers was analysed by a Hitachi SU 8030, 189 
(Hitachi High-Technologies, Germany) scanning electron microscope at low accelerating voltage 190 
(1 kV). Wafers were cut into thin slices and mounted on aluminium stubs (1 inch diameter) with 191 
‘Agar Scientific G3347N’ double sided adhesive carbon tape. Images of the wafers were 192 
acquired at a working distance of 15.0 mm at magnifications of 500-1500. 193 
 194 
2.6 X-ray diffraction (XRD) 195 
XRD analyses of the prepared wafers were performed using a D8 Advantage X-Ray 196 
diffractometer (Bruker AXS GmbH, Karlsure, Germany). The lyophilised wafers were 197 
compressed to a width size of 0.5 mm using a clean pair of compression glasses and mounted on 198 
the sample holder. The transmission diffractograms were acquired using DIFFRAC plus XRD 199 
Commander over a start to end diffraction angle of 2θ from 5° to 45°, step size of 0.02 and a 200 
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scan speed of 0.4 sec. X-ray patterns of the wafers and starting materials were obtained with 201 
DIFFRAC plus (Bruker Coventry, UK) having an XRD commander programme. A Goebbel 202 
mirror was used as monochromator which produced a focused monochromatic CuKα1&2 primary 203 
beam (λ=1.54184 Ǻ) with an exit slit of 0.6 mm. The detector used for performing the 204 
experiment was Lynx Eye. The operating condition during the experiment was 40 kV and 40 205 
mA. 206 
  207 
2.7 Differential scanning calorimetry (DSC) 208 
DSC analysis of the POL-CAR and POL-SA (BLK and DL) wafers and starting materials 209 
(CAR, SA, DLF and STP) was undertaken on a DSC1 Mettler Toledo instrument (Leicester, 210 
UK) calibrated with indium (based on heating range). Wafers were cut into small pieces and 3-5 211 
mg of sample was placed into 40µl aluminium pans with lids (Mettler Toledo, Leicester, UK) 212 
and sealed using crucible sealing press (Metler Toledo Leicester, UK). An empty aluminium pan 213 
sealed with lid was used as reference. A STARe software program was used to run the samples by 214 
initially cooling from 25°C to -50°C and then heated from (-50°C to 350°C) at the rate of 215 
10°C/min under constant purge of nitrogen (100 ml/min) to evaluate the thermal behaviour of the 216 
polymers and drugs present in the wafers. 217 
 218 
2.8 Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 219 
A FTIR spectrophotometer was used in combination with (Thermo Nicolet, 220 
Thermoscientific, UK), ZnSe attenuated total reflectance (ATR) accessory to characterise the 221 
wafers. The FTIR was equipped with potassium bromide (KBr) beam splitter and MCT detector. 222 
The wafers were placed on ZnSe ATR crystal (45°) and maximum pressure was applied by using 223 
a pressure clamp accessory to allow for intimate contact of the wafers with the ATR crystal. 224 
Similarly, the pure starting materials (POL, CAR, SA, STP and DLF) were analysed as controls. 225 
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Spectra were recorded at 4 cm-1 resolution within a range of 650-4000 cm-1 using OMNIC® 226 
software. True absorbance of each sample was obtained by background subtracting spectral 227 
information for the ATR crystal. 228 
 229 
2.9 Mechanical strength (‘hardness’)  230 
The mechanical properties (resistance to deformation and ease of recovery) of the freeze-231 
dried wafers were investigated by compressing on a Texture Analyser (TA) (Stable 232 
Microsystems Ltd., Surrey, UK) equipped with 5 kg load cell and Texture Exponent-32® 233 
software program18. Wafers were compressed using a 6 mm (P/6) cylindrical stainless steel 234 
probe (Stable Microsystems Ltd., Surrey, UK) in compression mode. The effects of compression 235 
speed (0.1-3.0 mm/sec) and depth of penetration (0.2-3.0 mm) on different wafers were 236 
evaluated. The ‘hardness’ (resistance to deformation) of the wafers were evaluated by 237 
compressing the sample at three different locations to a depth of 2 mm at a speed of 1 mm/sec 238 
using a trigger force of 0.001N and withdrawn till it lost complete contact with the wafer. Five 239 
wafers of each formulation [POL-CAR and POL-SA (NAn, An, and DL-An)] were compressed 240 
to determine the reproducibility in the response of the wafers to deformation by compression.  241 
 242 
2.10 Swelling studies 243 
Four different annealed (An) wafers POL-CAR-BLK-An, POL-CAR-DL-An, POL-SA-244 
BLK-An, and POL-SA-DL-An were used for the swelling studies. The swelling studies were 245 
carried out as described previously19. In brief, the wafers were immersed in simulated wound 246 
fluid (SWF) containing (2% bovine serum albumin, 0.02 M calcium chloride, 0.4 M sodium 247 
chloride, 0.08 M tris (hydroxyl) aminomethane in deionised water, pH 7.5) at room 248 
temperature20. The change in weight of the hydrated wafers was determined every 15 min up to 249 
120 min. The hydrated wafers were carefully blotted with tissue paper to remove excess SWF on 250 
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the surface and then weighed immediately on an electronic balance (European Instruments, UK). 251 
The effect of polymer and drugs on swelling performance was evaluated for the four 252 
formulations. Percentage swelling index  (%) was calculated using the equation 119. Where, 253 
Wd is dry weight of polymeric wafers and Ws denotes weight of the hydrated swollen wafer. 254 
Is =

× 		                               Equation 1 255 
 256 
2.11 In vitro adhesion studies 257 
 Adhesive measurements were performed on the wafers using a TA.HD plus Texture 258 
Analyser (Stable Micro Systems, Surrey, UK) fitted with a 5 kg load cell. The wafer (n = 4) was 259 
attached to an adhesive probe (75 mm diameter) using double sided adhesive tape. The surface 260 
of a 6.67 % w/v gelatine solution, allowed to set as a solid gel in a Petri dish (86 mm diameter), 261 
was equilibrated with 0.5 ml 2% w/w BSA containing SWF or 5% w/w BSA containing SWF to 262 
mimic a wound surface with thin and viscous exudate respectively. The probe, lined with wafer 263 
was set to approach the model wound surface with the following pre-set conditions: pre-test 264 
speed 0.5 mm/s; test speed 0.5 mm/s; post-test speed 1.0 mm/s; applied force 1 N; contact time 265 
60.0 s; trigger type auto; trigger force 0.05 N and return distance of 10.0 mm. The adhesive 266 
characteristics were determined by the maximum force (stickiness) required to detach the wafer 267 
from the model wound surface, total work of adhesion (WOA) was represented by the area under 268 
the force versus distance curve, whilst cohesiveness was defined as the distance travelled by 269 
wafer till detached and calculated using the Texture Exponent 32® software. 270 
 271 
2.12 In vitro drug dissolution studies 272 
 Drug assayed contents of STP and DLF within the wafers were determined before 273 
performing the drug dissolution studies. These were measured by cutting wafers from different 274 
sections of the wafers into small pieces, accurately weighed to 4 mg and hydrated in 10 ml of 275 
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distilled water at 37°C with stirring and left overnight to completely dissolve. The concentration 276 
of STP and DLF in distilled water was assayed by HPLC as described in 2.13. In vitro drug 277 
dissolution studies were performed with a Franz diffusion cell across a wire mesh using SWF 278 
(without BSA) at pH 7.5 as dissolution media in the receptor compartment. The pH 7.5 was 279 
chosen in order to represent the natural chronic wound environment which has been reported in 280 
range of 7.15–8.90 21. The SWF was prepared without BSA to avoid blocking the HPLC column. 281 
The DL wafers (POL-CAR-DL and POL-SA-DL) containing STP and DLF was placed on the 282 
wire mesh. The donor and receiver compartments were kept in intimate contact by wrapping 283 
Parafilm® at the junction between both compartments. POL-CAR-BLK and POL-SA-BLK were 284 
used as control. The temperature of the diffusion cell was maintained at 37±0.5°C by a 285 
circulating water jacket. The dissolution medium was constantly stirred throughout the 286 
experiments using magnetic beads on a magnetic stirrer. 1.0 ml aliquots of dissolution media 287 
were withdrawn at predetermined time intervals and analysed by HPLC and replaced with the 288 
same amount of SWF to maintain a constant volume throughout. The percentage cumulative 289 
release of STP and DLF from the wafers was calculated, taking into consideration the dilution 290 
due to the 1.0 ml aliquots that were discarded and replaced with fresh dissolution medium. The 291 
calculated values were plotted against time. 292 
 293 
2.13 HPLC analysis 294 
This was performed using an Agilent 1200 HPLC equipped with an auto sampler 295 
(Agilent Technologies, Cheshire, UK,) and a Chemstation® software program. The column used 296 
was a Hichrome (150 x 4.6 mm, 5µm) (Hichrome ltd; Berkshire, UK). The mobile phase 297 
consisted of phosphate buffer (pH 5.5) and acetonitrile in the ratio of 85:15 (v/v) for STP and 298 
deionised water and acetonitrile in the ratio of 40:60 (v/v) for DLF. The buffer was prepared by 299 
mixing 20mM of sodium hexane sulphonate and 25mM of tribasic sodium phosphate in distilled 300 
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water and pH adjusted to 5.5 using ortho-phosphoric acid. The flow rate of the mobile phase was 301 
maintained at 1.0 ml/min and detector wavelengths for STP and DLF were set at 195 nm and 284 302 
nm respectively. 20 µl volumes were injected during each run. Standards from 5-500µg/ml were 303 
used to plot calibration curves for STP and DLF (r2> 0.99). 304 
 305 
3 Results  306 
3.1 Freeze drying cycle development with annealing step  307 
Table 2 shows the DSC thermal transition profiles of gels evaluated from -60°C to 25°C 308 
which informed the freezing [annealing (An)/non-annealing (NAn)] stages during the 309 
development of the freeze drying cycle of the prepared polymeric gels. Glass-transition (Tg) 310 
temperature of -54.5°C and -56.9°C was observed for the POL-CAR gel and POL-SA gels 311 
respectively. The eutectic melts for both gels were observed between -8°C to -13°C and ice melts 312 
were observed between an onset of -1.0°C and endset of (6-11°C) which is associated with 313 
melting of ice in the interstitial spaces of the frozen cake. Table 2 also shows the transitions 314 
during the heating stage of the POL-CAR-An and POL-SA-An gels, where no glass transition 315 
but rather the eutectic melt [-10.5°C (POL-CAR-An gel), -9.5°C (POL-SA-An gel)] and ice melt 316 
[2.0°C (POL-CAR-An gel), 2.6°C (POL-SA-An gel)], were observed. The effectiveness of the 317 
annealing process was evidenced by the disappearance of the glass transition in the heating 318 
cycle.  319 
 320 
3.2 Formulation development and optimisation 321 
 The different wafers (POL-CAR-BLK, POL-CAR-DL, POL-SA-BLK, and POL-SA-DL) 322 
both annealed and non-annealed (An and NAn respectively) were visually examined for 323 
acceptable lyophilisation behaviour and physical elegance of the resulting product. All wafers 324 
prepared from the blending of POL-CAR and POL-SA were of uniform mass, texture and 325 
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thickness, soft and flexible especially POL-SA wafers which were softer and more pliable in 326 
nature compared to POL-CAR wafers.  327 
 328 
3.3 Scanning electron microscopy  329 
SEM images of POL-CAR-BLK (NAn and An), POL-CAR-DL-An, POL-SA-BLK (NAn 330 
and An) and POL-SA-DL-An wafers are shown in figure 2. POL-CAR-BLK-An and POL-SA-331 
BLK-An wafers formed a porous interconnecting network of polymeric strands having circular 332 
shaped pores after annealing. POL-CAR-BLK-NAn showed smaller pores with a leafy structure 333 
whilst POL-SA-BLK-NAn wafers showed elongated sponge-like strands with a less porous 334 
structure. POL-CAR-BLK-An wafers formed a sponge-like network whilst POL-SA-BLK-An 335 
wafers formed a less porous structure. Overall, the SEM images showed a tangible effect of 336 
annealing on the pore distribution of the wafers. 337 
The SEM images of POL-CAR-DL-An and POL-SA-DL-An wafers showed significant 338 
differences in surface topography. The POL-CAR-DL-An wafer at high drug loading (25% w/w 339 
DLF and 30% w/w STP based on total polymer weight) showed the least porosity as the surface 340 
texture appeared as leafy strands with irregular pores while the POL-SA-DL-An wafer (at 10% 341 
w/w DLF and 25% w/w STP based on total polymer weight) showed a more porous texture with 342 
uniform pore size distribution.  343 
 344 
3.4 Mechanical properties of wafers 345 
 Table 3 shows the effect of speed and depth of probe penetration on the ‘hardness’ 346 
(resistance to compression) of POL-CAR-BLK and POL-SA-BLK (NAn and An) in addition to 347 
POL-CAR-DL-An and POL-SA-DL-An wafers. The results show slight increases in the 348 
resistance to compressive deformation with increasing test speed. POL-CAR-BLK-NAn wafers 349 
showed high resistance to compressive forces at all speeds (0.2 - 3.0 mm) but was decreased for 350 
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the POL-CAR-BLK-An wafers. There were slight differences in the ‘hardness’ between the 351 
POL-CAR-BLK-An and POL-CAR-DL-An as well as between POL-SA-BLK-An and POL-SA-352 
DL-An wafers. Generally, the POL-CAR-An wafers (both BLK and DL) were stronger 353 
(‘harder’) than the corresponding POL-SA-An (BLK and DL) wafers. In the case of the POL-SA 354 
formulations, the difference between the BLK and DL wafers were less and also showed an 355 
effect opposite to that for POL-CAR. In other words, whereas the ‘hardness’ of the POL-CAR-356 
BLK-An (0.96 ± 0.1) was higher than POL-CAR-DL-An (0.74 ± 0.3), the value for POL-SA-357 
BLK-An (0.44 ± 0.1) was lower than POL-SA-DL-An (0.55 ± 0.1).  358 
When wafers were compressed to a greater penetration depth, the peak force required to 359 
deform the wafers increased due to the reduction in porosity of wafers at greater depths of 360 
compression and more intimate contact of the polymer chains. It was observed that a higher 361 
force was required for the probe to penetrate (2 mm) for all the wafers with increasing speed 362 
(Table 3). This may be due to the arrangement of the polymer network which resists penetration 363 
and requires a higher force with increased speed of compression. The POL-CAR (An and NAn) 364 
wafers showed significantly higher ‘hardness’ (p < 0.001) when compared with the POL-SA (An 365 
and NAn) wafers. This suggests that POL-CAR wafers showed a more rigid polymeric network 366 
than the POL-SA wafers and these results support the SEM observations.  367 
 368 
3.5 X-ray diffraction (XRD) 369 
 Figure 3 shows XRD transmission diffractograms of POL, SA, CAR, DLF and STP. Pure 370 
POL was semi-crystalline in nature which showed sharp peaks at 14.62°, 15.05°, 19.11°, 23.22°, 371 
26.23° and 26.91° whereas CAR indicated an amorphous nature with the presence of peak at 372 
28.39°, and 40.58° which may be attributed to inorganic salt impurities, mainly potassium 373 
chloride (KCl)22. STP and SA were amorphous whilst DLF was highly crystalline in nature. 374 
XRD diffractograms of annealed wafers prepared from POL-CAR and POL-SA (BLK and DL) 375 
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are also shown in figure 3. POL-CAR-BLK-An and POL-SA-BLK-An wafers showed decreased 376 
intensities at 19.11°, 23.22° which indicates that the crystallinity of POL was reduced in the 377 
presence of CAR and SA. Further, POL-SA-BLK-An wafers showed decreased intensities due to 378 
the relatively higher ratio of SA compared to CAR. All the drug loaded wafers did not show 379 
distinct peaks of DLF and STP, however, there was a peak observed at 31.73° which may be 380 
associated with the formation of sodium sulphate associated with the DLF and STP.  381 
 382 
3.6 Differential scanning calorimetry (DSC) 383 
Figure 4 shows the DSC thermograms for pure polymers, pure drugs and their 384 
corresponding wafers. STP showed a broad endothermic peak at 152.7°C which undergoes 385 
recrystallization and then eventually melts. This may be associated with the presence of basic 386 
guanido moieties and relatively weakly basic methylamino functional groups which are 387 
responsible for two melt peaks and needs further investigation. SA showed a glass transition 388 
peak at 60.3°C with subsequent endothermic peaks at 152.7°C, whereas CAR showed an 389 
endothermic peak at 148.8°C which consequently decomposed at 192.6°C with a sharp 390 
exothermic peak. DLF showed melting peaks at 293.9°C in addition to immediate 391 
decomposition. POL showed an endothermic peak at 70.2°C with an exothermic peak at 177.2°C 392 
which could be attributed to the recrystallization from the melt. DSC curves of all POL-CAR and 393 
POL-SA (BLK and DL) An wafers showed a reduction in the intensity of the POL melting peak 394 
(59 - 61°C) due to the molecular chain of CAR and SA which has a significant effect on the 395 
overall chain mobility in the mixture and retards the rate of crystal growth of POL12.  396 
POL-CAR-BLK-An wafers further showed an exothermic peak at 130°C due to the POL 397 
but this was absent in the POL-CAR-DL-An wafers due to the drug-polymer interaction. POL-398 
CAR (BLK-An and DL-An) wafers showed endothermic peaks between (162 - 164°C) which 399 
may be associated with CAR. POL-CAR (BLK-An and DL-An) wafers showed exothermic 400 
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peaks at 212.3°C and 270.4°C respectively which may be due to the interactions between the 401 
polymer and drug. POL-SA (BLK-An and DL-An) wafers showed an endothermic peak at 402 
135.3°C and 139.9°C and exothermic peak 238.7°C and 242.2°C possibly due to the effect of 403 
added SA. Wafers showed hydrogen bonding interaction between the polymer blends of POL-404 
SA and POL-CAR which confirms the compatibility of these polymers. Both POL-CAR-DL-An 405 
and POL-SA-DL-An wafers did not show any peaks for DLF and STP which suggests the 406 
molecular dispersion of the drugs within the wafer matrix.  407 
 408 
3.7 Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 409 
Figure 5 shows the ATR-FTIR spectra of POL-CAR and POL-SA (BLK-An, and DL-410 
An) wafers. The spectra show the respective absorption peaks of POL at 1100cm-1 due to C-O-C 411 
asymmetric stretching. An absorption band at 2885cm-1 was also attributed to CH symmetric 412 
stretching vibration in POL, while absorption bands at 1465cm-1, 1242cm-1, 1278cm-1 and 413 
958cm-1 were associated with CH2 scissoring, asymmetric  twisting and wagging respectively. 414 
CAR showed an absorption peak at 1232cm-1 due to the presence of sulphate ester moiety. The 415 
peaks at 924cm-1, 844cm-1, 890cm-1 and 1155cm-1 were respectively assigned to 3, 6 416 
anhydrogalactose residue, galactose 4-sulphate, C-H stretching of β-galactopyranosyl residue 417 
and C-O stretching of pyranose ring of the CAR. In the FTIR spectrum of SA, C-O stretching of 418 
uronic acid, C-C, C-O stretching and C-OH deformation vibrations were observed at 929cm-1, 419 
1024cm-1, 1084cm-1, 1400cm-1 respectively. DLF showed the characteristic peak at 1402cm-1, 420 
1573cm-1 which is due to the O-C-O symmetric and asymmetric stretching, whilst the observed 421 
peaks at 1556cm-1, 1602cm-1, 1585cm-1 are associated with ring stretching. Peaks at 1469cm-1 422 
and 1450cm-1 were due to C-N stretching. The same stretching band of C-N at 1458cm-1 was 423 
observed for STP. Primary NH2, O-H and C-O-C stretching at 3365cm-1, 3201cm-1 and 1035cm-1 424 
respectively was observed for STP.  425 
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Monitoring the band shift at 1100cm-1 C-O-C stretching for the BLK and DL POL-CAR 426 
and POL-SA wafers showed hydrogen bonding or complexation between the POL and both CAR 427 
and SA. Intermolecular interaction between the POL with CAR or SA was responsible for the 428 
increased physical stability of the prepared wafers. The DL wafers did not show any 429 
characteristic peaks of DLF due to the homogeneous mixing into the POL-CAR and POL-SA 430 
polymeric matrix. However, the presence of C=N and N-H stretching band at 1618cm-1-1654cm-431 
1
 confirmed the presence of STP in all the POL-CAR (DL) wafers. 432 
 433 
3.8 Swelling studies 434 
 Figure 6 shows the change in swelling capacity (%) of the wafers with time. The 435 
difference in the hydration capacity of the optimised POL-CAR-BLK-An wafer (3770 ± 283%) 436 
and POL-SA-BLK-An (1711 ± 46%) was statistically significant (p = 0.0001). The POL-CAR-437 
BLK-An wafers showed high swelling capacity which was dramatically decreased in the POL-438 
CAR-DL-An wafers (1450 ± 62%). This difference was also observed between the POL-SA-439 
BLK-An and POL-SA-DL-An wafers even though the differences were only noticeable during 440 
the first 40 minutes. The POL-SA-DL-An wafer showed a maximum swelling capacity of only 441 
1227 ± 134%.  442 
POL-CAR-BLK-An showed higher swelling capacity than the POL-SA-BLK-An, which 443 
may be due to the use of different polymers in different ratios (75/25 and 50/50, respectively). In 444 
the initial 30 min, the swelling index of both DL wafers (POL-CAR-DL-An and POL-SA-DL-445 
An) were the same which further decreased for POL-SA-DL-An but were consistently increasing 446 
for POL-CAR-DL-An.  447 
 448 
 449 
 450 
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3.9 Adhesion studies 451 
 Figure 7 shows the effect of two different concentrations of BSA (2% w/w and 5% w/w) 452 
representing thin (watery) and viscous exudate respectively, on adhesion properties of POL-CAR 453 
and POL-SA (BLK-An and DL-An) wafers. POL-CAR-BLK-An and POL-SA-BLK-An wafers 454 
showed similar (4.9 ± 1.3N and 4.7 ± 1.1N respectively) stickiness values in the presence of thin 455 
SWF (2% w/w BSA) whereas the stickiness was decreased in POL-CAR-DL-An and POL-SA-456 
DL-An wafers. WOA and cohesiveness were higher in the POL-SA (BLK-An and DL-An) 457 
wafers which decreased for POL-CAR (BLK-An and DL-An) wafers. Both POL-CAR-BLK-An 458 
and POL-SA-BLK-An wafers showed high stickiness in the presence of viscous SWF (5% w/w 459 
BSA) which decreased for the POL-SA-DL-An and POL-CAR-DL-An wafers. It was observed 460 
that WOA decreased in descending order for POL-CAR-BLK-An, > POL-SA-BLK-An, > POL-461 
SA-DL-An wafers. There was a significant difference (p = 0.0010) in stickiness and WOA 462 
between BLK-An and DL-An of both POL-CAR and POL-SA wafers. Overall, the POL-CAR-463 
BLK-An wafers showed higher stickiness and WOA in the presence of viscous SWF (5% w/w 464 
BSA) whereas POL-CAR-DL-An wafers had higher stickiness and WOA in the presence of 465 
normal or thin SWF (2% w/w BSA). However, POL-SA-BLK-An and POL-SA-DL-An wafers 466 
showed higher stickiness and WOA in the presence of SWF (2% w/w BSA) compared to SWF 467 
(5% w/w BSA). In the presence of SWF (2% w/w BSA) POL-CAR (BLK-An and DL-An) had 468 
similar values while POL-SA (BLK-An and DL-An) showed significant differences in the 469 
cohesiveness (p = 0.0200).  470 
 471 
3.10 In vitro drug release study 472 
 Figure 8 shows the dissolution profiles of STP and DLF from annealed POL-CAR-DL 473 
and POL-SA-DL wafers. The drug loading capacities for POL-CAR-DL-An wafers were 68.2 ± 474 
1.1% (STP) and 90.2 ± 1.0% (DLF) whilst that for the POL-SA-DL-An wafers were 61.8 ± 475 
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18.4% (STP) and 93.9 ± 4.7% (DLF) (n = 3). The total cumulative percent of STP released in 72 476 
h from the POL-CAR-DL-An wafer and POL-SA-DL-An wafers were 81.4 ± 3.8% and 79.6 ± 477 
4.9%, respectively which was statistically significant (p = 0.0189), though both formulations 478 
exhibited a sustained (controlled) release of STP.  479 
Model dependent methods based on mathematical functions were used to describe the 480 
dissolution profiles of STP and DLF released from the wafers. These included zero order, first 481 
order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas models. Release parameters obtained 482 
from fitting experimental dissolution release data to the different kinetic equations have been 483 
summarised in Table 3. The slope (n) values ranged from 0.57 - 0.60 for STP and 0.60 - 0.84 for 484 
DLF in the case of wafers. The in-vitro release profiles of STP from the wafers could best be 485 
described by Korsmeyer-Peppas equation which showed the highest linearity (R2 = 0.90 - 0.99) 486 
compared to the other equations (Table 4).  487 
 488 
4. Discussion 489 
The formulations with different ratios were selected based on preliminary studies 490 
undertaken with different hydrophilic polymers each at different combinations of concentrations 491 
with POL as part of the wider study12. The formulations in different w/w ratios, 75/25 for POL-492 
CAR and 50/50 for POL-SA were selected on the basis of their ease of handling such as pouring 493 
and also forming clear transparent films that were better than POL (1% w/w) on its own 494 
(published in our previous article). In the future, we plan to compare the in vivo performance of 495 
the films and wafers and we wanted their polymer content to be comparable as this affects 496 
hydration, swelling, drug release and bioadhesion significantly. 497 
According to Zivanovic and co-workers, formulations prepared from only synthetic 498 
polymers such as polyethylene oxide have relatively poor physical characteristics such as 499 
stickiness and high water solubility which limit their application26. Generally, formation of 500 
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specific intermolecular interactions through weak hydrogen bonding between two or more 501 
polymers is responsible for the observed behaviour of formulations prepared from aqueous gels 502 
comprising blends of polymers. The good film forming ability of CAR has been explored for the 503 
development of wound healing patches for the treatment of topical burn wounds23. A naturally 504 
occurring polymer (CAR) was added to POL to modify and improve the properties of the latter 505 
as well, due to its reported use for wound application. Hydrogel dressings containing polyvinyl 506 
alcohol, CAR and agar have been used in clinical trials on human patients which showed safety 507 
and efficacy of the dressing. Such dressings have been used in treatment of burns, non-healing 508 
diabetic ulcers, leprosy and other external wounds. This dressing is now being marketed in India 509 
under different brand names24. 510 
To avoid the formation of a metastable glass which will eventually crystallize and affect 511 
the stability of the formulations, samples were heated to above the measured glass transition 512 
temperature (but below the eutectic and/or ice melting temperature) of the mixture and 513 
temperature returned to the original freezing temperature. This allowed the glass to relax and 514 
crystallize during the freezing stage. It has previously been demonstrated that gels which are 515 
annealed between the glass transition and eutectic melt peaks improves the metastable state14. 516 
This leads to transformation of its structure towards a more relaxed state and is manifested by an 517 
improvement in functional characteristics such as hydration, adhesion and drug release 518 
properties of the formulations14. Based on the thermal events observed during the heating cycle, 519 
an annealing temperature of -25°C was chosen and incorporated into the thermal treatment for 520 
the freezing step of the lyophilisation cycle. This facilitated the fusion of smaller ice crystals 521 
together, to form larger crystals that leave large pores following ice sublimation14. 522 
 The temperature selection for the freezing of the sample was to improve the homogeneity 523 
of crystallisation and formation of a porous ice cake 25. Consequently, sponge-like, porous 524 
polymeric network of uniform and large pores that are regularly distributed throughout the 525 
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wafers were observed in figure 2 for POL-CAR-BLK-An and POL-SA-BLK-An wafers. The 526 
annealed wafers also had better elegance as compared to the non-annealed wafers. These wafers 527 
were deemed flexible enough to allow ease of handling for their application as an effective 528 
wound dressing with a low likelihood of causing contact irritation. To avoid collapse of the cake, 529 
primary drying of the sample was carried out at -25ºC at low pressure. Low chamber pressure 530 
allows for a high sublimation rate and homogenous heat transfer from the sample and for that 531 
purpose, chamber pressure was maintained between 20-50 mTorr.  532 
The changes in the surface structure and reduced porosity of POL-CAR-DL-An wafers 533 
could be attributed to the different amounts of STP and DLF incorporated in the wafer’s matrix. 534 
In terms of applications, the differences observed in the pore size morphologies of the POL-535 
CAR-BLK An and NAn wafers can affect functional properties such as rate of hydration, 536 
swelling, adhesion and consequent drug release characteristics in the presence of wound 537 
exudate. Wafers with high porosity can absorb high exudate due to high water ingress which 538 
leads to high swelling and subsequent diffusion of drug from the swollen matrix1,18. Highly 539 
exuding chronic wounds such as diabetic foot and venous ulcers limit the application of 540 
dressings such as films due to the high amount of exudate which causes maceration at the 541 
wound site. Further, annealed POL-SA-DL-An wafers may offer a better drug delivery system 542 
due to their more porous nature compared to POL-CAR-DL-An wafer, and can therefore absorb 543 
high exudate volumes and also keep the wound environment moist for rapid healing. However, 544 
excessive hydration may cause wafer wetting and formation of slippery mucilage which can 545 
decrease the adhesion properties at the wound site13,16. 546 
For wound healing purposes, the freeze dried wafers are expected to encounter various stresses 547 
during its handling and application and therefore necessitates optimum mechanical strength, so 548 
as to maintain their structural integrity during and after application 26. ‘Hardness’ is the measure 549 
of the peak force required to deform the wafer to the required depth of penetration. The 550 
Page 22 of 45Journal of Pharmaceutical Sciences
23 
 
differences in hardness values observed between the POL-CAR and POL-SA wafers may be 551 
related to the different amounts of CAR and SA used in their respective formulations which may 552 
affect both how they interact with both POL and the loaded drug. Furthermore, the differences in 553 
the number, size and shape of pores between POL-CAR and POL-SA wafers could account for 554 
these differences in mechanical strength measured on the texture analyser18.  555 
The effect of speed and depth of compression on hardness are critical, as significant 556 
changes to wafer dimensions could affect properties such as its pore size18. Such variations if 557 
large enough (POL-CAR-BLK-NAn and POL-CAR-BLK-An) may result in significant changes 558 
in hydration, swelling and possibly drug release characteristics which ultimately affect its 559 
performance as a wound dressing for controlled drug delivery. However, this will need to be 560 
further investigated. Based on these results and the SEM observations, only annealed wafers 561 
were used for all subsequent investigations. 562 
 The crystalline properties of polymeric formulations affect various characteristics such as 563 
water uptake, bioadhesion and biodegradability of the polymers27. Wafers prepared from the 564 
POL-CAR and POL-SA showed decreased crystallisation of POL which may help to improve its 565 
properties stated above and therefore improve the performance of the dressing such as exudate 566 
absorption, prolonged retention at wound site which can ultimately increase the bioavailability of 567 
the drug and reduce the need for frequent change of dressing. The reduction in POL 568 
crystallization by SA and CAR is probably a result of interruption of POL-POL interactions 569 
because of formation of hydrogen bonds between the ether and hydroxyl groups from POL and 570 
SA or CAR respectively28. This decreased crystallanity of POL-CAR and POL-SA blends and 571 
the molecular dispersion of STP and DLF will have high surface energy due to less ordered 572 
amorphous structures than the more crystalline form. The increase in the surface energy allows 573 
greater molecular interaction between the solute and solvent hence they are more soluble and are 574 
expected to release the drugs (STP and DLF) quickly when applied to the wound site which can 575 
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help to reduce bacterial infection. However, it is important to maintain the amorphous form 576 
during storage since high energy levels in such form may cause a reversion back to the 577 
crystalline form of POL and DLF (which are respectively semi-crystalline and crystalline in 578 
nature) and needs further evaluation through long term stability studies. 579 
However, Huang and co-workers reported that molecularly dispersed drug prompted by 580 
hydrogen bonding between drug and polymers had improved physical stability which did not 581 
affect release kinetics of the drug 29. Such molecularly dispersed drug in the polymer matrix 582 
helps to improve physical stability and drug release from the dosage forms. This can help to 583 
maintain biological as well as environmental stability of STP and DLF and their expected 584 
controlled release will help to reduce the need for frequent dressing change dressing with 585 
improved wound healing 29. 586 
The water uptake (swelling) of the samples reached the maximum value within 30 min of 587 
incubation, due to hydrophilicity of the POL, CAR and SA in the presence of SWF. In addition, 588 
the annealing process enhanced ice crystal size during the freezing stage and subsequently 589 
increase wafer porosity. The highly porous structure of freeze-dried wafers allowed a rapid 590 
ingress of water initially which affected the swelling capacity. It is interesting to note that the 591 
wafers maintained their structural integrity after 2 h of incubation at 37ºC due possibly to the 592 
mechanically stronger formulations obtained by annealing. This may be due to the effect of 593 
added drug which decreased the porosity (SEM data) as well as the formation of sodium sulphate 594 
which decreased the swelling capacity of wafers. Singh and co-workers reported the effect of 595 
sodium sulphate on gels of the polysaccharide, agarose. They showed that the hydration capacity 596 
of agarose polysaccharide decreased with increasing concentration of sodium sulphate which is 597 
associated with strong hydrophobic hydration of the highly osmotropic sodium sulphate 30. The 598 
presence of sodium sulphate formed in the polymeric gels (POL-CAR and POL-SA) appears to 599 
be behaving in the same manner to reduce the swelling capacity of the DL wafers compared with 600 
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the BLK wafers. The mechanism behind this reduction is that a part of the total sodium sulphate 601 
present in the gel is used to reduce the interactions of hydrophilic -OH groups of CAR and SA 602 
with water molecules, thereby reducing the organization of water molecules into a tetrahedral 603 
arrangement in the vicinity of hydrated CAR and SA. The marked influence of sodium sulphate 604 
on the swelling index of POL-SA-DL-An and POL-CAR-DL-An may further affect the drug 605 
release through the wafers. Both (BLK and DL) wafers showed appropriate exudate holding 606 
capacity while maintaining their structural integrity for prolonged periods and therefore could 607 
help to overcome the challenge of excess exudate collecting under the dressing1. 608 
It is also possible that other factors apart from sodium sulphate maybe at play during 609 
hydration and swelling. For the systems containing SA (POL-SA-BLK and POL-SA-DL) the 610 
plateau regions of the swelling profiles could be due to the hydrogel formation caused by 611 
divalent calcium ions (Ca2+) naturally present in alginates, which can exchange with sodium ions 612 
to form strong crosslinked hydrogels. In the case of systems containing CAR (POL-CAR-BLK 613 
and POL-CAR-DL) the decreasing trend of the profiles could be due to a partial solubilization of 614 
the systems which reduces their overall moisture holding capacity. 615 
The adhesive characteristics showed differences between the BLK and DL wafers which 616 
again may be because of the presence of sodium sulphate in DL wafers which has a marked 617 
effect on the initial hydration of the wafers resulting in decreased stickiness. Cohesiveness is the 618 
intermolecular attraction which holds the wafer and the model wound substrate together. Usually 619 
thin watery serous type exudate (represented by 2% BSA SWF) in a wound signifies possible 620 
bacterial infection. S. aureus and Streptococci produce staphylokinase which has fibrinolytic 621 
activity and degrades fibrin clots resulting in thin watery exudate 31, 32. The POL-CAR-DL-An 622 
and POL-SA-DL-An wafers can help to manage such exudate due to their porous nature. 623 
Haemorrhagic and haemopurulent (viscous and sticky) exudate signifies infection and trauma 624 
and POL-CAR (BLK-An and DL-An) wafers can provide prolonged retention of wafers at the 625 
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site of such wounds. Overall, adhesion results from both BLK-An and DL-An wafers confirmed 626 
that the porosity plays a critical role due to the ability to absorb SWF and hydration of the 627 
polymeric network (POL, SA and CAR). The decreased stickiness in the DL wafers was 628 
associated with the decreased porosity of these wafers due to the added drugs and subsequent 629 
sodium sulphate formation which inhibit rapid hydration of the wafers.  630 
From the results obtained, it can be concluded that the wafers generally possessed good 631 
adhesive strength with the wound substrate containing two different types of exudate. Therefore 632 
these wafers are expected to adhere to the wound site and protect the wound from the external 633 
environment, with the absorption of large amounts of exudate, which is a primary requirement 634 
for a formulation to function as an ideal wound dressing. Generally, the force and work of 635 
adhesion values appear high and raises the issue of maintaining a balance between prolonged 636 
retention at the wound site and the need to avoid damaging sensitive newly formed tissue during 637 
the healing process in the course of dressing change. However, it should be noted that high 638 
adhesion will also reduce the need for frequent dressing changes and could therefore mitigate 639 
against damage to new tissues arising from high frequency of dressing changes. Further, normal 640 
moist dressings encounter a continuous flow of produced exudate which is expected to reduce 641 
the bioadhesion during the duration of application, compared to the current study where the 642 
volume of simulated fluid was kept constant. This however, requires further investigation during 643 
an in vivo study. 644 
The rate of release was faster from the POL-CAR-DL-An wafers than the POL-SA-DL-645 
An wafers within the first hour of release and attributed to the different ratios of POL, where 646 
POL-CAR wafer swelled more quickly and formed a gel that easily hydrated in the SWF during 647 
the initial stages of drug dissolution. Bunte and co-authors observed that drug release is 648 
facilitated by the porous network of lyophilised wafers33. An increased surface area of the 649 
dispersed drug in the porous cake occurs, accelerating dissolution significantly. The difference 650 
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in the drug released from both formulations may also be associated with the varying amount of 651 
STP and DLF present which can affect the drug release rate. As discussed previously in the 652 
swelling studies, POL-SA-DL wafers showed less swelling than the POL-CAR-DL-wafers 653 
which was also responsible for the slow release of STP. Both wafers showed very slow and 654 
constant release of DLF from the formulations with only 30-33% of DLF released from both 655 
wafers and might be attributed to its relatively poor water solubility as well as sodium sulphate 656 
which affected the hydration capacity of the wafers.  657 
The slope (n) values from the Korsmeyer-Peppas equation, which characterises the 658 
release mechanism of drugs from cylindrical matrices (for wafers) can serve as an indication for 659 
diffusion controlled drug release, assuming wafer geometry with negligible edge effects, time- 660 
and position-independent diffusion coefficients in a non-swellable and insoluble matrix former. 661 
In contrast, if polymer swelling is the sole release rate controlling mechanism, zero order drug 662 
release kinetics are observed corresponding to a release exponent of n = 1. Release exponents 663 
that are in-between these extreme values for the respective device geometry indicate so-called 664 
anomalous or non-Fickian diffusion transport, with an overlapping of different types of 665 
phenomena, potentially including drug diffusion and polymer swelling 34. Drug release from 666 
swellable matrices is usually complex and though some processes may be distinctly classified as 667 
either diffusion or erosion controlled, drug release is mostly governed by both mechanisms. 668 
Analysis of the experimental data using the Korsmeyer-Peppas equation, and interpretation of 669 
the release exponents (n), provides a better understanding of the mechanisms controlling 670 
release. Release exponents of POL-CAR-DL-An and POL-SA-DL-An wafers show an 671 
anomalous (non-Fickian) transport, suggesting that both diffusion of STP and DLF through the 672 
hydrated swollen polymer combined with gel erosion controlled drug release. 673 
In the current study, the sterilization effect on the freeze-dried wafers was not 674 
investigated. However, the wafers will not be able to withstand heat or steam sterilization owing 675 
Page 27 of 45 Journal of Pharmaceutical Sciences
28 
 
to the potential to cause structural collapse due to moisture. The most suitable in our view will be 676 
gamma irradiation at a suitable dose. This was proved by Matthews and co-workers16 who 677 
showed its suitability for sterilising freeze-dried polymeric wafers. At high doses, gamma rays 678 
were reported to cause a reduction in the rheological viscosity of the polymeric gels obtained 679 
from the wafers due possibly to breaking of hydrogen bonding. This will need further 680 
investigation in relation to the POL-CAR and POL-SA wafers used in this study. 681 
 682 
5. Conclusions 683 
Characterisation of the two different wafers (POL-CAR and POL-SA) (BLK-An and DL-684 
An) showed significant differences in their microscopic structure and physical properties which 685 
is expected to impact on their wound healing performance characteristics. The annealing step in 686 
the lyophilisation cycle helped to produce soft, flexible and desired porous structure in the 687 
formulated wafers. This helped to improve mechanical strength, ease of hydration, adhesion and 688 
the in vitro drug release characteristics of the DL wafers. Further, the annealing step reduced the 689 
hardness of the wafers but remained strong enough to potentially withstand the mechanical 690 
stresses occurring during day-to-day activities, while flexible enough to prevent potential 691 
damage to newly formed skin tissue. DSC and XRD studies showed decreased crystallanity of 692 
the POL with molecular dispersion of the drugs within the wafer polymer matrix.  Such 693 
dispersion of both drugs can improve the physical stability of the dosage form and controlled 694 
release of both drugs which can potentially help to improve wound healing by acting on two 695 
different stages of wound healing. The results show that the annealed wafers may be potentially 696 
used for highly exuding wounds such as chronic ulcers. However, this will need to be confirmed 697 
by further investigations in future in vivo animal studies. 698 
 699 
 700 
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Figure Legends 799 
Figure 1: Schematic diagram of the lyophilisation cycle, incorporating an annealing step, used 800 
for the preparation of wafers. 801 
Figure 2: SEM images of POL-CAR-BLK-NAn, POL-CAR-BLK-An, POL-CAR-DL-An, POL-802 
SA-BLK-NAn, POL-SA-BLK-An, POL-SA-DL-An showing differences in porous 803 
microstructure due to annealing and presence of drug. 804 
Figure 3: XRD diffractograms of pure polymers (SA, CAR and POL), drugs (STP and DLF) and 805 
POL-CAR and POL-SA (BLK and DL) wafers. 806 
Figure 4: DSC profiles of the pure polymers, (SA, CAR and POL), drugs (STP and DLF) and 807 
POL-CAR and POL-SA (BLK-An and DL-An) wafers. 808 
Figure 5: ATR-FTIR spectra showing peaks for different components within freeze dried POL-809 
CAR and POL-SA (BLK-An and DL-An) wafers. 810 
Figure 6: Swelling profiles (% swelling index against time) of POL-CAR and POL-SA wafers 811 
in the presence of normal SWF (mean ± SD, n=4). 812 
Figure 7: Adhesion results showing the moist wound adhesion properties of POL-CAR and 813 
POL-SA wafers with SWF containing 2% w/w BSA and 5% w/w BSA.  814 
Figure 8: In vitro drug release profiles of STP and DLF from POL-SA-DL-wafer and POL-815 
CAR-DL-wafer showing plot of mean percent cumulative release (± SD, n=3) against time in the 816 
presence of SWF. 817 
 818 
 819 
  820 
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Table 1: Composition of polymers and drugs in gels used for freeze dried wafers. The final 
polymer concentration was 1 % w/w 
Starting material 
 
POL-CAR-BLK POL-CAR-DL 
Weight (g) 
POL-SA-BLK POL-SA-DL 
 
POL 0.75 0.75 0.50 0.50 
CAR 0.25 0.25 - - 
SA - - 0.50 0.50 
STP - 0.30 - 0.25 
DLF - 0.25 - 0.10 
Total weight  1.00 1.55 1.00 1.35 
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Table 2: DSC of thermal transitions of the POL-CAR and POL-SA gels (NAn and An) frozen to -60°C and then reheated to and held at -25°C. 
The results show no transitions around -25°C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samples (gels) Temperature (°C) 
Glass transition Eutectic melt Ice melt 
Onset Midpoint Onset Peak Endset Onset Peak  Endset 
POL-CAR  -55.8 -54.5 -12.4 -10.1 -8.5 -0.4 3.0 7.3 
POL-CAR-An  - - -13.5 -10.5 -8.65 -0.9 2.0 6.8 
POL-SA  -58.3 -56.9 -11.6 -9.7 -8.2 -0.8 3.5 8.9 
POL-SA-An  - - -11.2 -9.5 -8.3 -1.0 2.6 11.1 
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Table 3: Texture analysis data showing changes in mechanical resistance of the various wafers with different formulation and instrumental 
variables (speed of compression, depth of penetration and annealing during freeze-drying 
   Force (N)    
Speed (mm/s) POL-CAR-BLK  
(NAn) 
POL-CAR-BLK 
(An) 
POL-CAR-DL 
(An) 
POL-SA-BLK 
(NAn) 
POL-SA-BLK 
(An) 
POL-SA-DL 
(An) 
n = 5 Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
0.2 1.62 ± 0.2 0.91 ± 0.1 0.63 ± 0.0 0.47 ± 0.1 0.27 ± 0.1 0.38 ± 0.1 
0.5 1.72 ± 0.1 0.96 ± 0.3 0.69 ± 0.1 0.51 ± 0.1 0.34 ± 0.1 0.47 ± 0.1 
1.0 1.82 ± 0.1 0.97 ± 0.2 0.71 ± 0.1 0.63 ± 0.1 0.29 ± 0.1 0.51 ± 0.1 
2.0 1.96 ± 0.4 0.96 ± 0.1 0.77 ± 0.0 0.50 ± 0.1 0.44 ± 0.1 0.55 ± 0.1 
3.0 2.16 ± 0.1 1.31 ± 0.3 0.72 ± 0.1 0.63 ± 0.1 0.46 ± 0.1 0.58 ± 0.1 
Depth (mm) POL-CAR-BLK 
(NAn) 
POL-CAR-BLK 
(An) 
POL-CAR-DL 
(An) 
POL-SA-BLK 
(NAn) 
POL-SA-BLK 
(An) 
POL-SA-DL  
(An) 
n = 5 Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
0.2 0.75 ± 0.2 0.04 ± 0.0 0.06 ± 0.0 0.03 ± 0.0 0.02 ± 0.0 0.04 ± 0.0 
0.5 0.92 ± 0.2 0.14 ± 0.0 0.20 ± 0.1 0.23 ± 0.1 0.06 ± 0.0 0.08 ± 0.0 
1.0 1.24 ± 0.2 0.45 ± 0.1 0.38 ± 0.1 0.34 ± 0.1 0.17 ± 0.0 0.18 ± 0.1 
1.5 1.57 ± 0.2 0.77 ± 0.1 0.54 ± 0.0 0.51 ± 0.1 0.23 ± 0.1 0.37 ± 0.1 
2.0 1.57 ± 0.2 0.96 ± 0.1 0.66 ± 0.0 0.50 ± 0.1 0.35 ± 0.1 0.51 ± 0.2 
3.0 1.80 ± 0.3 1.19 ± 0.3 0.90 ± 0.0 0.80 ± 0.1 0.54 ± 0.1 0.66 ± 0.2 
‘Hardness’ POL-CAR-BLK 
(NAn) 
POL-CAR-BLK 
(An) 
POL-CAR-DL 
(An) 
POL-SA-BLK 
(NAn) 
POL-SA-BLK 
(An) 
POL-SA-DL  
(An) 
n = 4 Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
(N) 1.06 ± 0.4 0.96 ± 0.1 0.74 ± 0.3 0.50 ± 0.1 0.44 ± 0.1 0.55 ± 0.1 
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Table 4: Release parameters obtained from fitting experimental drug dissolution (release) data to different kinetic equations for wafers 
containing STP and DLF.   
 
 
Formulation Zero order First order Higuchi  Hixon Crowell Korsmeyer-Peppas 
 K0 R
2
 K1 R
2 
KH (% min
1/2
) R
2 
KHC (% min
-1/3
) R
2 
KP (% min
-n
) n R
2 
STP 
POL-CAR-DL-An 0.28 0.58 0.004 0.97 4.260 0.97 -0.005 0.95 0.400 0.60 0.95 
POL-SA-DL-An 0.20 0.54 0.001 0.95 3.010 0.97 -0.003 0.93 0.320 0.57 0.97 
DLF 
POL-CAR-DL-An 0.28 0.58 0.004 0.97 4.260 0.97 -0.005 0.95 0.400 0.60 0.95 
POL-CAR-DL-An 0.28 0.58 0.004 0.97 4.260 0.97 -0.005 0.95 0.400 0.60 0.95 
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